These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12706527)

  • 1. Endopeptidase character of monoclonal antibody i41-7 subunits.
    Hatiuchi K; Hifumi E; Mitsuda Y; Uda T
    Immunol Lett; 2003 May; 86(3):249-57. PubMed ID: 12706527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How and why 41S-2 antibody subunits acquire the ability to catalyze decomposition of the conserved sequence of gp41 of HIV-1.
    Hifumi E; Okamoto Y; Uda T
    Appl Biochem Biotechnol; 2000; 83(1-3):209-19; discussion 219-20, 297-313. PubMed ID: 10826961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catalytic features of monoclonal antibody i41SL1-2 subunits.
    Hifumi E; Kondo H; Mitsuda Y; Uda T
    Biotechnol Bioeng; 2003 Nov; 84(4):485-93. PubMed ID: 14574707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catalytic antibody light chain capable of cleaving a chemokine receptor CCR-5 peptide with a high reaction rate constant.
    Mitsuda Y; Hifumi E; Tsuruhata K; Fujinami H; Yamamoto N; Uda T
    Biotechnol Bioeng; 2004 Apr; 86(2):217-25. PubMed ID: 15052642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Removal of catalytic activity by EDTA from antibody light chain.
    Hifumi E; Ohara K; Niimi Y; Uda T
    Biometals; 2000 Dec; 13(4):289-94. PubMed ID: 11247034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of active form of catalytic antibody light chain 41S-2-L.
    Mitsuda Y; Tsuruhata K; Hifumi E; Takagi M; Uda T
    Immunol Lett; 2005 Jan; 96(1):63-71. PubMed ID: 15585309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catalytic digestion of human tumor necrosis factor-α by antibody heavy chain.
    Hifumi E; Higashi K; Uda T
    FEBS J; 2010 Sep; 277(18):3823-32. PubMed ID: 20718866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA (A*0201) mimicry by anti-idiotypic monoclonal antibodies.
    Burlingham WJ; Jankowska-Gan E; DeVito-Haynes L; Fechner JH; Hogan KT; Claas FH; Mulder A; Wang X; Ferrone S
    J Immunol; 1998 Dec; 161(12):6705-14. PubMed ID: 9862700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted destruction of the HIV-1 coat protein gp41 by a catalytic antibody light chain.
    Hifumi E; Mitsuda Y; Ohara K; Uda T
    J Immunol Methods; 2002 Nov; 269(1-2):283-98. PubMed ID: 12379368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-cyclosporine monoclonal antibodies and their anti-idiotopic counterpart: structure and biological activity.
    Zenke G; Zeder G; Strittmatter U; Andersen E; Kocher HP; Quesniaux VF; Schreier MH; Van Regenmortel MH
    Mol Immunol; 1992 Mar; 29(3):343-51. PubMed ID: 1557045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular analysis of anti-idiotypic monoclonal antibodies in the HLA-DR antigenic system.
    Armandola EA; Mariani SM; Zwickl M; Hardman N; Ferrone S
    Eur J Immunol; 1992 Nov; 22(11):2893-9. PubMed ID: 1425914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiotypic analysis of anti-I-Ak monoclonal antibodies. I. Production and characterization of syngeneic anti-idiotypic mAb against an anti-I-Ak mAb.
    Phillips ML; Harris JF; Delovitch TL
    J Immunol; 1984 Nov; 133(5):2587-94. PubMed ID: 6434633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mouse monoclonal anti-idiotypic antibodies to HIV p24: immunochemical properties and internal imagery.
    Hohmann A; Peters V; Comacchio R; Bradley J
    Mol Immunol; 1993 Apr; 30(6):521-7. PubMed ID: 8487775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure and binding properties of a monoclonal anti-idiotypic autoantibody to anti-DNA with epibody activity.
    Fischel R; Eilat D
    J Immunol; 1992 Nov; 149(9):3089-96. PubMed ID: 1401933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gangliosides, Ab1 and Ab2 antibodies II. Light versus heavy chain: An idiotype-anti-idiotype case study.
    López-Requena A; Rodríguez M; de Acosta CM; Moreno E; Puchades Y; González M; Talavera A; Valle A; Hernández T; Vázquez AM; Pérez R
    Mol Immunol; 2007 Feb; 44(5):1015-28. PubMed ID: 16620986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topology of an amiloride-binding protein.
    Lin C; Kieber-Emmons T; Villalobos AP; Foster MH; Wahlgren C; Kleyman TR
    J Biol Chem; 1994 Jan; 269(4):2805-13. PubMed ID: 8300613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary structure of light and heavy chain variable regions of antibodies recognizing phosphorylated vimentins.
    Tsujino S; Sekimata M; Inagaki N; Kamie Y; Higashihara M; Kurokawa K; Imajoh-Ohmi S; Inagaki M
    Biochem Biophys Res Commun; 1996 Feb; 219(2):633-7. PubMed ID: 8605039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production and characterization of monoclonal antibodies to porcine immunoglobulin gamma, alpha, and light chains.
    Paul PS; Mengeling WL; Malstrom CE; Van Deusen RA
    Am J Vet Res; 1989 Apr; 50(4):471-9. PubMed ID: 2469366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new algorithm to convert a normal antibody into the corresponding catalytic antibody.
    Hifumi E; Taguchi H; Tsuda H; Minagawa T; Nonaka T; Uda T
    Sci Adv; 2020 Mar; 6(13):eaay6441. PubMed ID: 32232151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purification of reduced and alkylated antibody subunits.
    Sun M; Paul S
    Methods Mol Biol; 1995; 51():111-22. PubMed ID: 7581690
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.